Clinical trial NCT01541332: Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma
Official title: A Phase 1/2 Study of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients With Relapsed/Refractory Multiple Myeloma
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
PHASE2
Conditions: Multiple Myeloma
Keywords: relapsed refractory
multiple myeloma
pomalidomide
Doxil
dexamethasone
Oncotherapeutics
Lead sponsor: Oncotherapeutics
Sponsor class: INDUSTRY
Collaborators: name: Celgene Corporation
First posted: 2012-02-29
Enrollment: 70
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this clinical research study is to evaluate the safety and effectiveness (good and bad effects) of a combination of three different drugs, pomalidomide, pegylated liposomal doxorubicin, and dexamethasone when used to treat relapsed (the disease came back) or refractory (the disease did not respond to past treatment) multiple myeloma. Different dosages (amount of study drug) of pomalidomide are first being tested to determine if there are any side effects or risks associated with combining this study drug with the other two listed. Once the optimal dose is decided on, the study will change its focus to determining the effectiveness of the study drug in this combination.

Detailed description: This is a phase 1/2, multicenter, open label and nonrandomized study to evaluate the efficacy and safety of pomalidomide at daily dosages of 2, 3 or 4 mg in combination with intravenous (IV) dexamethasone at 40 mg/dose and Pegylated Liposomal Doxorubicin (PLD) at 5 mg/m2/dose for subjects with relapsed/refractory multiple myeloma (MM). The study consists of a screening period, followed by up to eight 28 day open label treatment cycles, a final assessment to occur 28 days after the end of the last treatment, and a follow-up period.

Subjects eligible for this study will receive treatment with study drug for a maximum of eight 28 day treatment cycles. Subjects are to be treated to a maximum response plus 2 additional cycles (no more than 8 cycles will be allowed) or complete 8 cycles of therapy without disease progression.

Pomalidomide, dexamethasone and PLD will be administered on the appropriate cycle days as shown below.

Cohort 1 Pomalidomide\* - 2 mg, Dexamethasone\*\* - 40 mg, PLD\*\* - 5 mg/m2

Cohort 2 Pomalidomide\* - 3 mg, Dexamethasone\*\* - 40 mg, PLD\*\* - 5 mg/m2

Cohort 3 Pomalidomide\* - 4 mg, Dexamethasone\*\* - 40 mg, PLD\*\* - 5 mg/m2

\* PO Days 1-21

\*\* IV Days 1, 4, 8 and 11

In all cohorts, if an unacceptable dose limiting toxicities (DLT) is not seen in any of the 3 subjects during the first cycle of any dose level, dose escalation will continue. All subjects in a cohort must complete a minimum of 28 days or a full cycle, whichever is longer, without a DLT before enrollment to the next cohort can begin. If a DLT is identified in 1 subject at any dose level during the first treatment cycle, an additional 3 subjects will be recruited to this dose level. A maximum of 6 subjects may be enrolled in each cohort. If an unacceptable DLT is observed in 2 subjects at any dose level, no further subjects will be recruited to this dose level. The maximum tolerated dose (MTD) will be declared as the highest dose level at which fewer than 33% of subjects experienced an unacceptable DLT. If pomalidomide at 4 mg is reached and fewer than 33% of subjects experience an unacceptable DLT, 4 mg will be accepted as the putative MTD. Once the MTD is established, further enrollment will continue to expand that dose cohort until the total sample size of 40 subjects is reached for the entire study. During the phase 2 portion of this study, subjects enrolled will have relapsed/refractory MM resistant to lenalidomide as demonstrated by progressive disease while on lenalidomide or that has relapsed within 8 weeks of the last dose of lenalidomide.

Eligibility criteria: Inclusion Criteria:

* Diagnosis of MM based on standard criteria (Durie 1986)
* Currently has MM with measurable disease, defined as:

  * a monoclonal immunoglobulin spike on serum electrophoresis of at least 0.5 g/dL and/or
  * urine monoclonal protein levels of at least 200 mg/24 hours
  * for patients without measurable serum and urine M-protein levels, an abnormal free light chain ratio (normal value: 0.26 - 1.65)
* Currently has progressive MM that has relapsed or is refractory, defined as:

  * For the phase 1: Relapsed following stabilization or a response to at least one anti-myeloma regimen or refractory defined as progressed while receiving an anti-myeloma treatment
  * For the phase 2: Refractory to lenalidomide as demonstrated by progressive disease while on lenalidomide or that relapsed within 8 weeks of the last dose of lenalidomide either as a single agent or in combination.
  * Prior treatment with four days or less of a total of 400 mg of prednisone (or an equivalent potency of another steroid) for MM will not be considered a regimen
* Able to adhere to the study visit schedule and other protocol requirements
* ECOG performance status of 2 or greater at study entry
* Life-expectancy of greater than 3 months
* Lab tests within study ranges at study entry:

  * Absolute neutrophil count \> 1.5 x 109/L
  * Platelet count \> 75 x 109/L
  * Hemoglobin \> 8 g/dL
  * Calculated or measured creatinine clearance \> 30 mL/minute
  * Total bilirubin \< 1.5 x upper limit of normal (ULN)
  * AST (SGOT) and ALT (SGPT) \< 2 x ULN
  * Serum potassium within the normal range
* Females of childbearing potential must have a negative serum or urine pregnancy test.
* Able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (subjects intolerant to ASA may use warfarin or low molecular weight heparin)

Exclusion Criteria:

* POEMS syndrome
* Plasma cell leukemia
* Primary amyloidosis
* Non-hematologic malignancy within the past 5 years with the exception of a) adequately treated basal cell carcinoma, squamous cell skin cancer, or thyroid cancer; b) carcinoma in situ of the cervix or breast; c) prostate cancer of Gleason Grade 6 or less with stable prostate-specific antigen levels; or d) cancer considered cured by surgical resection or unlikely to impact survival during the duration of the study, such as localized transitional cell carcinoma of the bladder or benign tumors of the adrenal or pancreas
* Impaired cardiac function or clinically significant cardiac diseases
* Severe hypercalcemia
* Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the ICF
* Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study
* Undergone major surgery within 28 days prior enrollment or has not recovered from side effects of such therapy (Kyphoplasty is not considered to be a major surgery; however, the investigator is to discuss enrollment of a subject with a recent history of kyphoplasty with the medical monitor)
* Pregnant or breast feeding females. (Lactating females must agree not to breast feed while taking lenalidomide)
* Received the following prior therapy:

  * Pomalidomide
  * Chemotherapy within 3 weeks of study drugs (6 wks for nitrosoureas)
  * Corticosteroids (\>10 mg/day prednisone or equivalent) within 3 weeks of study drugs
  * Immunotherapy or antibody therapy as well as thalidomide, lenalidomide, arsenic trioxide or bortezomib within 21 days before study drugs
  * Extensive radiation therapy within 28 days before study drugs. Receipt of localized radiation therapy does not preclude enrollment.
  * Use of any other experimental drug or therapy within 28 days of study drugs
* Known hypersensitivity to compounds of similar chemical or biological composition to thalidomide, lenalidomide or doxorubicin.
* The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs
* Concurrent use of other anti-cancer agents or treatments
* Known positivity for human immunodeficiency virus (HIV) or hepatitis B or C; baseline testing for HIV and hepatitis B or C is not required

Primary outcomes:
measure: MTD of Pomalidomide
timeFrame: 12 months
measure: Overall Response Rate
timeFrame: 24 months
Secondary outcomes:
measure: Number of Patients with Adverse Events
timeFrame: 24 months
measure: Time to Progression
timeFrame: 24 Months
measure: Progression-free Survival
timeFrame: 24 Months
measure: Time to First Response
timeFrame: 24 Months
measure: Duration of Response
timeFrame: 24 Months
measure: Overall Survival
timeFrame: 24 Months
Other outcomes:
Locations:
city: Burbank
country: United States
facility: Roy and Patricia Disney Family Cancer Center
state: California
city: Encinitas
country: United States
facility: California Cancer Associates for Research and Excellence
state: California
city: Fresno
country: United States
facility: Hematology Oncology Medical Group
state: California
city: Salinas
country: United States
facility: Pacific Cancer Care
state: California
city: Santa Barbara
country: United States
facility: Cancer Center of Santa Barbara
state: California
city: Santa Maria
country: United States
facility: Mission Hope Cancer Center
state: California
city: West Hollywood
country: United States
facility: James R Berenson, MD, Inc.
state: California
city: Niles
country: United States
facility: Illinois Cancer Specialists
state: Illinois
Study officials:
affiliation: Oncotherapeutics
name: James R Berenson, MD
role: PRINCIPAL_INVESTIGATOR
References: